Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New U.K. NHS Bodies Authorize Avastin Use In AMD As Lucentis Pricing Pressures Continue

You may also be interested in...

Italy's Move To Fund Off-label Avastin Use In AMD May Be Illegal, Pharma Groups Say

EFPIA, Novartis and Roche believe that a decision by the Italian regulatory authority, AIFA to allow reimbursement for the off-label use of Avastin in place of Lucentis may be against EU law.

Italy Wants €1.2 Billion From Novartis And Roche In Lucentis/Avastin Saga

The Italian government has said it will pursue Roche and Novartis for €1.2 billion it says the Swiss companies owe to its health service for anticompetitive activities involving Avastin and Lucentis.

EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines

With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts